ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 170 filers reported holding ASCENDIS PHARMA A/S in Q3 2021. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $605,136,441 | +20.8% | 4,954,855 | +2.1% | 3.63% | +10.7% |
Q3 2022 | $501,085,000 | +11.1% | 4,852,655 | 0.0% | 3.28% | +28.3% |
Q2 2022 | $451,103,000 | -15.4% | 4,852,655 | +6.8% | 2.56% | -16.5% |
Q1 2022 | $533,003,000 | -12.8% | 4,541,604 | 0.0% | 3.06% | +3.0% |
Q4 2021 | $610,982,000 | -15.6% | 4,541,604 | 0.0% | 2.97% | -6.5% |
Q3 2021 | $723,886,000 | +55.4% | 4,541,604 | +28.3% | 3.18% | +55.5% |
Q2 2021 | $465,723,000 | +2.1% | 3,540,270 | 0.0% | 2.04% | +3.4% |
Q1 2021 | $456,270,000 | -22.7% | 3,540,270 | 0.0% | 1.98% | -11.1% |
Q4 2020 | $590,446,000 | +8.1% | 3,540,270 | 0.0% | 2.22% | +1.9% |
Q3 2020 | $546,334,000 | +9.0% | 3,540,270 | +4.4% | 2.18% | -1.3% |
Q2 2020 | $501,421,000 | +31.3% | 3,390,270 | 0.0% | 2.21% | -5.9% |
Q1 2020 | $381,778,000 | -19.1% | 3,390,270 | 0.0% | 2.35% | -6.2% |
Q4 2019 | $471,654,000 | +44.4% | 3,390,270 | 0.0% | 2.51% | +12.9% |
Q3 2019 | $326,551,000 | -16.4% | 3,390,270 | 0.0% | 2.22% | -16.3% |
Q2 2019 | $390,390,000 | -2.2% | 3,390,270 | 0.0% | 2.65% | +3.9% |
Q1 2019 | $399,035,000 | +124.5% | 3,390,270 | +19.5% | 2.55% | +75.4% |
Q4 2018 | $177,760,000 | -11.6% | 2,837,352 | 0.0% | 1.46% | +10.0% |
Q3 2018 | $201,055,000 | +6.5% | 2,837,352 | 0.0% | 1.32% | -6.6% |
Q2 2018 | $188,741,000 | +1.7% | 2,837,352 | 0.0% | 1.42% | -9.9% |
Q1 2018 | $185,563,000 | +76.9% | 2,837,352 | +8.3% | 1.57% | +73.0% |
Q4 2017 | $104,910,000 | +23.2% | 2,618,818 | +11.5% | 0.91% | +31.5% |
Q3 2017 | $85,145,000 | +75.1% | 2,348,840 | +34.1% | 0.69% | +62.6% |
Q2 2017 | $48,621,000 | +28.5% | 1,751,463 | +29.6% | 0.42% | +37.1% |
Q1 2017 | $37,841,000 | +82.7% | 1,351,463 | +32.1% | 0.31% | +52.7% |
Q4 2016 | $20,711,000 | +38.2% | 1,023,266 | +37.3% | 0.20% | +49.3% |
Q3 2016 | $14,985,000 | +51.5% | 745,521 | 0.0% | 0.14% | +30.8% |
Q2 2016 | $9,893,000 | +5.5% | 745,521 | +47.5% | 0.10% | +5.1% |
Q1 2016 | $9,377,000 | +1.3% | 505,521 | 0.0% | 0.10% | +28.6% |
Q4 2015 | $9,261,000 | +20.1% | 505,521 | +16.1% | 0.08% | +8.5% |
Q3 2015 | $7,709,000 | +336.0% | 435,540 | +335.5% | 0.07% | +343.8% |
Q2 2015 | $1,768,000 | +1.9% | 100,000 | 0.0% | 0.02% | +14.3% |
Q1 2015 | $1,735,000 | – | 100,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |